CLAIMS

1. Use of a combination drug in the manufacture of a medicament for treating or putting an elderly solid cancer patient or a terminal solid cancer patient into remission, wherein the combination drug comprises a pharmaceutical composition comprising, as active ingredients, (2S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoylamino]-4-methylpentanoic acid or a pharmacologically acceptable salt thereof, and a molecular targeted drug selected from the group consisting of erlotinib, axitinib, gefitinib, crizotinib, and afatinib, wherein the (2S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoylamino]-4-methylpentanoic acid or pharmacologically acceptable salt is contained in an amount administered to the elderly cancer patient or the terminal solid cancer patient at a dose of 10mg per administration once a day, the molecular targeted drug is contained at a dose not more than its usually administered dose, and the elderly solid cancer patient is 70 years of age or older.

2. Use of a kit preparation in the manufacture of a medicament for treating or putting an elderly solid cancer patient or a terminal solid cancer patient into remission, wherein the kit preparation comprises, as active ingredients, a pharmaceutical composition comprising (2S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoylamino]-4-methylpentanoic acid or a pharmacologically acceptable salt thereof, and a molecular targeted drug selected from the group consisting of erlotinib, axitinib, gefitinib, crizotinib, and afatinib, wherein the (2S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoylamino]-4-methylpentanoic acid or pharmacologically acceptable salt is contained in an amount administered to the elderly cancer patient or the terminal solid cancer patient at a dose of 10mg per administration once a day, the molecular targeted drug is contained at a dose not more than its usually administered dose, and the elderly solid cancer patient is 70 years of age or older.

3. The use according to claim 1 or 2, wherein the elderly solid cancer patient or the terminal solid cancer patient has a 4 or higher neutrophil count to lymphocyte count ratio in peripheral blood, or a 1.5 or higher platelet count to lymphocyte count ratio in peripheral blood, or a normal range of 130000-350000 platelet counts/μL or a normal range of 2000-6800 neutrophil counts/mm^3 in peripheral blood.

4. The use according to any one of claims 1-3, wherein the elderly solid cancer patient or the terminal solid cancer patient has a cancer selected from the group consisting of colon or colorectal cancer, breast cancer, thyroid gland cancer, lung cancer, gallbladder/bile duct cancer, or renal cancer, and a metastatic cancer thereof.